P78 Thrombotic thrombocytopenic purpura (TTP) in an SLE patient successfully treated with plasma exchange, caplacizumab and rituximab
Main Authors: | Branimir Anic, Ivan Padjen, Marija Bakula |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2024-03-01
|
Series: | Lupus Science and Medicine |
Similar Items
-
Successful use of a second course of caplacizumab in relapsed thrombotic thrombocytopenic purpura
by: Jon Shaffer, et al.
Published: (2022-07-01) -
Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura (HERCULES trial)
by: Estcourt, L
Published: (2019) -
Caplacizumab as an emerging treatment option for acquired thrombotic thrombocytopenic purpura
by: Elverdi T, et al.
Published: (2019-04-01) -
Caplacizumab for immune thrombotic thrombocytopenic purpura: real-world multicenter data
by: Eleni Gavriilaki, et al.
Published: (2023-10-01) -
P1609: CAPLACIZUMAB THERAPY IN OLDER PATIENTS (≥60 YEARS) WITH IMMUNE THROMBOTIC THROMBOCYTOPENIC PURPURA (ITTP). RESULTS OF THE SPANISH TTP REGISTRY
by: Javier DE LA Rubia, et al.
Published: (2023-08-01)